1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. ViroPharma Acquires Lev Pharmaceuticals

M&A Deal Summary

ViroPharma Acquires Lev Pharmaceuticals

On October 21, 2008, ViroPharma acquired life science company Lev Pharmaceuticals for 586M USD

Acquisition Highlights
  • This is ViroPharma’s 1st transaction in the Life Science sector.
  • This is ViroPharma’s largest (disclosed) transaction.
  • This is ViroPharma’s 1st transaction in the United States.
  • This is ViroPharma’s 1st transaction in New York.

M&A Deal Summary
Date 2008-10-21
Target Lev Pharmaceuticals
Sector Life Science
Buyer(s) ViroPharma
Deal Type Add-on Acquisition
Deal Value 586M USD
Advisor(s) Willkie Farr & Gallagher
Becker (Legal)

Target

Lev Pharmaceuticals

New York, New York, United States
Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ViroPharma

Exton, Pennsylvania, United States
Category Company
Founded 1994
Sector Life Science
DESCRIPTION

ViroPharma, Inc. is a pharmaceutical company committed to the commercialization, development, and discovery of new antiviral medicines.

DEAL STATS #
Overall 1 of 3
Sector: Life Science M&A 1 of 3
Type: Add-on Acquisition M&A Deals 1 of 3
State: New York M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2008 M&A 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-05-28 Auralis

Halton, United Kingdom

Auralis developed generic pharmaceutical products for niche markets, which were subject to licence or regulatory approval providing barriers to entry to protect margin and revenue.

Buy -
Mergr

Solution for

Product

Company

Legal